Moreover, LAV‐BPIFB4 improved the diabetes‐induced impairment in endothelial‐dependent vasorelaxation and eNOS phosphorylation (Figure6E–G), without affecting vasorelaxation by nitroglycerine (Figure6H). Here, BPIFB4 is linked to diabetes mellitus.